Payment & Shipping Terms:
|Product Name:||Trelagliptin Succinate||Synonyms:||Trelagliptin Succinate - SYR 111472 Succinate | SYR 472;SRY-472;Telagliptin Succinate;Trelagliptin Succinate, >=98%;2-[[6-[(3R)-3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile,butanedioicacid;Trelagliptin Succinate API;|
[PRODUCT NAME]:Trelagliptin succinate
[APPEARANCE]: White Crystal Powder
Trelagliptin succinate Chemical Properties
Trelagliptin succinate Usage And Synthesis
|Uses||Trelagliptin succinate (SYR-472) is a selective, long acting dipeptidyl peptidase-4 (DPP-4) inhibitor. An antidiabetic agent.
Orally active DPP-4 inhibitor that produces clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. SYR472 has a long duration of action and is well tolerated in clinical studies.
|Clinical Use||Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor used for the treatment of type 2 diabetes mellitus. Trelagliptin (as the salt Trelagliptin succinate) was approved for use in Japan in March 2015. Takeda, the company that developed Trelagliptin, chose to not get approval for the drug in the USA and EU.|
|Research||Trelagliptin (Zafatek) is an orally active DPP-4 inhibitor developed by Takeda and approved in Japan for the treatment of type 2 diabetes mellitus (T2DM). Unlike other approved agents of its class, which are usually administered once daily, trelagliptin can be administered once weekly. Phase II development of trelagliptin was discontinued in the USA and EU, as Takeda considered that the costs associated with obtaining approval in these markets were prohibitive.|
Contact Person: Ruze01